These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 8635858

  • 1. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA.
    Int J Cancer; 1996 May 16; 66(4):441-52. PubMed ID: 8635858
    [Abstract] [Full Text] [Related]

  • 2. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T, Toet K, Quax P, Kooistra T.
    Kidney Int; 1999 Jan 16; 55(1):120-9. PubMed ID: 9893120
    [Abstract] [Full Text] [Related]

  • 3. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
    Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T.
    J Pathol; 1997 Dec 16; 183(4):388-97. PubMed ID: 9496254
    [Abstract] [Full Text] [Related]

  • 4. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
    Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T.
    Am J Pathol; 2000 Feb 16; 156(2):567-75. PubMed ID: 10666386
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR, Moestrup SK, van den Berg BM, Pannekoek H, Nielsen MS, van Zonneveld AJ.
    J Biol Chem; 1995 May 19; 270(20):11770-5. PubMed ID: 7538122
    [Abstract] [Full Text] [Related]

  • 6. Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
    Sałuda-Gorgul A, Pytel J, Olborski B, Greger J.
    Z Naturforsch C J Biosci; 2002 May 19; 57(3-4):366-71. PubMed ID: 12064742
    [Abstract] [Full Text] [Related]

  • 7. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A, Kjøller L, Cohen RL, Lawrence DA, Garni-Wagner BA, Todd RF, van Zonneveld AJ, Gliemann J, Andreasen PA.
    J Biol Chem; 1994 Oct 14; 269(41):25668-76. PubMed ID: 7929271
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
    Dublin E, Hanby A, Patel NK, Liebman R, Barnes D.
    Am J Pathol; 2000 Oct 14; 157(4):1219-27. PubMed ID: 11021826
    [Abstract] [Full Text] [Related]

  • 9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 14; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 10. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG.
    Cancer; 1996 Mar 15; 77(6):1079-88. PubMed ID: 8635127
    [Abstract] [Full Text] [Related]

  • 11. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.
    Nonaka T, Kikuchi H, Ikeda T, Okamoto Y, Hamanishi C, Tanaka S.
    J Rheumatol; 2000 Apr 15; 27(4):997-1004. PubMed ID: 10782829
    [Abstract] [Full Text] [Related]

  • 12. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF.
    Breast Cancer Res Treat; 2000 May 15; 61(1):1-12. PubMed ID: 10930085
    [Abstract] [Full Text] [Related]

  • 13. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
    Xiao W, Tong WL, Ma DD.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov 15; 29(11):723-6. PubMed ID: 17327049
    [Abstract] [Full Text] [Related]

  • 14. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
    Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F.
    J Cell Biol; 1995 Dec 15; 131(6 Pt 1):1609-22. PubMed ID: 8522616
    [Abstract] [Full Text] [Related]

  • 15. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells.
    Zhang JC, Sakthivel R, Kniss D, Graham CH, Strickland DK, McCrae KR.
    J Biol Chem; 1998 Nov 27; 273(48):32273-80. PubMed ID: 9822706
    [Abstract] [Full Text] [Related]

  • 16. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thøgersen HC, Munch M, Andreasen PA.
    J Biol Chem; 1992 Jul 25; 267(21):14543-6. PubMed ID: 1378833
    [Abstract] [Full Text] [Related]

  • 17. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H.
    Cancer; 2006 Mar 01; 106(5):1026-35. PubMed ID: 16435385
    [Abstract] [Full Text] [Related]

  • 18. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C, Gavin O, Kruithof EK.
    Thromb Haemost; 2000 Feb 01; 83(2):290-6. PubMed ID: 10739388
    [Abstract] [Full Text] [Related]

  • 19. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
    Guiducci S, Del Rosso A, Cinelli M, Perfetto F, Livi R, Rossi A, Gabrielli A, Giacomelli R, Iori N, Fibbi G, Del Rosso M, Cerinic MM.
    Arthritis Res Ther; 2005 Feb 01; 7(6):R1244-53. PubMed ID: 16277677
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-1beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells.
    Chung HW, Wen Y, Ahn JJ, Moon HS, Polan ML.
    J Clin Endocrinol Metab; 2001 Mar 01; 86(3):1332-40. PubMed ID: 11238529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.